Novo Nordisk A/S annual free cash flow for fiscal TTM was $31.0 billion, an increase of 7.0% from $29.0 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Free Cash Flow (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | $31.0B | $29.0B | $69.7B | $70.0B | $64.1B | $47.6B | $29.9B | $35.6B | $32.2B | $32.5B | $40.0B | $31.9B | $27.4B | $22.3B | $18.6B | $18.0B | $15.8B | $12.3B | $10.9B | $7.6B | $4.4B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Free Cash Flow (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | $12.0B | ($36.2B) | $30.7B | $24.5B | $10.0B | ($4.3B) | $31.3B | $37.3B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More NVO metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Shares Outstanding
All NVO financial statements → Interactive NVO charts →
About TickerBase · Data methodology & sources